ChromaDex (NASDAQ:CDXC – Get Rating) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday.
CDXC has been the topic of several other reports. LADENBURG THALM/SH SH cut their target price on ChromaDex from $7.50 to $6.60 in a report on Thursday, May 11th. HC Wainwright cut their target price on ChromaDex from $5.50 to $5.00 and set a “buy” rating on the stock in a report on Monday, March 13th.
ChromaDex Stock Down 1.0 %
NASDAQ CDXC opened at $1.51 on Wednesday. ChromaDex has a twelve month low of $1.15 and a twelve month high of $2.37. The company has a market cap of $112.82 million, a price-to-earnings ratio of -10.03 and a beta of 1.79. The business’s fifty day moving average is $1.47 and its 200 day moving average is $1.66.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of ChromaDex by 9.5% in the 1st quarter. Vanguard Group Inc. now owns 2,781,437 shares of the company’s stock worth $6,842,000 after acquiring an additional 240,414 shares in the last quarter. Tieton Capital Management LLC raised its position in shares of ChromaDex by 20.6% in the 4th quarter. Tieton Capital Management LLC now owns 2,745,024 shares of the company’s stock worth $4,612,000 after acquiring an additional 469,429 shares in the last quarter. State Street Corp raised its position in shares of ChromaDex by 4.1% in the 1st quarter. State Street Corp now owns 932,526 shares of the company’s stock worth $2,294,000 after acquiring an additional 36,308 shares in the last quarter. Millennium Management LLC bought a new position in shares of ChromaDex in the 2nd quarter worth about $1,275,000. Finally, Renaissance Technologies LLC raised its position in shares of ChromaDex by 76.0% in the 2nd quarter. Renaissance Technologies LLC now owns 739,900 shares of the company’s stock worth $1,236,000 after acquiring an additional 319,399 shares in the last quarter. 42.81% of the stock is owned by institutional investors.
ChromaDex Company Profile
Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.
- Get a free copy of the StockNews.com research report on ChromaDex (CDXC)
- Airline ETFs: What They Are and How to Invest
- Williams-Sonoma Is The Retail Value Play, Here’s Why
- Ladder Corporation: Climbing Higher And Paying 9% Yield
- Microbot Medical spikes 150% on its Endovascular Surgical Robot
- PetMed Express: Charts Say This Could Be The Bottom
Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.